Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive business model that leverages cutting-edge technologies. The company has developed a promising pipeline addressing critical unmet medical needs in neurology, immunology, and rare diseases, which positions it well to streamline the drug development process while managing costs effectively. With a leadership team rich in industry experience and a network of strategic partnerships, Roivant is poised to drive financial growth and improve patient outcomes, making it an attractive investment opportunity for institutional investors.
| Revenue (TTM) | $7.53M |
| Gross Profit (TTM) | $-723.89M |
| EBITDA | $-1.36B |
| Operating Margin | -25408.00% |
| Return on Equity | -8.52% |
| Return on Assets | -16.50% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $5.86 |
| Price-to-Book | 5.88 |
| Price-to-Sales (TTM) | 3349.81 |
| EV/Revenue | 2805.02 |
| EV/EBITDA | 0.74 |
| Quarterly Earnings Growth (YoY) | -96.10% |
| Quarterly Revenue Growth (YoY) | -33.50% |
| Shares Outstanding | $722.32M |
| Float | $580.42M |
| % Insiders | 21.44% |
| % Institutions | 78.40% |
Volatility is currently expanding
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis Transcript
Roivant Sciences NASDAQ: ROIV said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered commercial launch.
Roivant and partner Priovant Therapeutics on Friday set a list price of $35,000 for a 30-day supply of their newly approved rare disease drug, Lisraya.
The U.S. Food and Drug Administration said on Thursday it approved a treatment from Roivant and partner Priovant Therapeutics for a rare disease, making it the first oral drug for the condition affecting skin and muscles.
BASEL, Switzerland and LONDON and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). LISRAYA is a pill taken once daily.
DURHAM, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). LISRAYA is a pill taken once daily.
DURHAM, N.C., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics announced today the publication in JAMA Dermatology of skin-specific outcomes from the Phase 3 VALOR trial evaluating brepocitinib, a first-in-class oral TYK2 and JAK1 inhibitor, in adults with dermatomyositis (DM). Primary efficacy and safety results from the trial were previously published in the New England Journal of Medicine, including benefit on measures of skin disease, muscle strength, physical function, and steroid-sparing.
Roivant Sciences NASDAQ: ROIV said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline.
Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.33 per share in line with the Zacks Consensus Estimate.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ROIV and any ticker you trade — then tracks every position and per-strategy win rate.
